Immuno-Oncology Webinar: Immunotherapy Cancer Combinations – When, Who and at What Price?
This article was originally published in Scrip
Executive Summary
Immuno-oncology may be seen as the future of cancer therapy, but it is combination therapy that is the future of immuno-oncology. The potential to use different types of these novel immune-acting products together to boost cancer control is as exciting in its potential as it is mind-boggling in its complexity. In this third Immuno-Oncology Webinar in Informa's series, our team of experts use exclusive data and insight to delve into the world of combination cancer immunotherapies.
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.